This site has been optimized to work with modern browsers and does not fully support your version of Internet Explorer.

System leadership

System Leadership: OAHP plays an important role in developing national resources used by biomedical scientists across the UK to discover and translate for the benefit of patients, in genomics, informatics, AI
and gene therapy:

  • OAHP worked together to achieve the establishment of OH BRC dedicated to brain health and neuroscience (the only entirely new BRC awarded in the 2016 competition, and still 1 of only 2 mental health BRCs nationally);
  • OAHP’s NIHR BRCs contribute and lead across all major NHS/UK health challenges and priorities.
  • In Big Data, Informatics, and AI, OAHP led development of the UK Biobank, (Sir Rory Collins), a unique programme that created the world’s largest and deepest high-quality resource for the correlation of clinical
    phenotypes and biological markers including genomics. This resource is an asset for global scientific studies and publications, primarily by non-Oxford centres.
  • OAHP is pioneering the use of new informatics-based approaches for large scale clinical trials via ‘digital recruitment’ such as the ORION4 trial of PCSK9 siRNA for cardiovascular disease prevention with The Medicines
  • Oxford BRC led the establishment of the NIHR Health Informatics Collaborative (HIC), bringing together all NIHR BRC NHS Trusts nationally to make clinical data readily available to researchers, industry and the wider
    NHS community. OUH and OH are Global Digital Exemplar NHS Trusts. OAHP leads the Innovate-UK National Consortium for Intelligent Medical Imaging (NCIMI) that will provide access to large-scale NHS imaging
    datasets across multiple NHS Trusts, for academic and commercial partners to develop and apply AI-based imaging solutions.
  • In Genomics, OAHP has played a pivotal role in bringing whole genome sequencing (WGS) into mainstream clinical practice. OAHP’s WGS500 project was the first large-scale test of clinical WGS in patients and families,
    demonstrating utility across multiple disease areas, underpinning the creation of Genomics England.
  • OAHP has taken a leadership position in Tissue, Cell and Gene Therapy academically and commercially, developing advanced therapies:
    • The Oxford BRC spinout, Nightstar (sold to Biogen for $800m) generated new vectors to treat inherited blindness and is now undertaking 1st in human phase 2b trials.
    • The £30m Nucleic Acid Therapeutics Accelerator (NATA) on Oxfordshire’s Harwell campus will develop new therapies and technologies targeting genetic mutations in diseases including muscular dystrophies, cancer, Huntingdon’s, Parkinson’s and arthritis.
    • OAHP surgeons and engineers developed biomimetic materials (Bioyarn, Biopatch, manufactured in OAHP’s GMP facilities), now in clinical trials to provide biophysical cues to improve tissue repair and healing in orthopaedic and reconstructive surgery.
    • The Oxford Institute of Developmental and Regenerative Medicine (IDRM, under construction) will mobilise expertise across cardiology, immunology and neuroscience, to develop advanced therapies for immune, cardiovascular and neurological disease.
    • OAHP leads the development of recombinant gene- and viral-vectored vaccines to tackle many of the world’s infectious disease challenges including: Universal Influenza A, MERS, Zika, HBV, and Malaria. The recent single-dose typhoid conjugate Typhoid vaccine (developed within the Oxford BRC, now approved by WHO), will transform the problem of antibiotic-resistant typhoid in children.
  • OAHP will play leadership roles with regional, national and international partners in target and drug discovery, for example the UoO-led Rosalind Franklin Institute at Harwell, a national facility that benefits from substantial OAHP support